B Glass1, M Ziepert2, M Reiser3, M Freund4, L Trümper5, B Metzner6, A Feller7, M Loeffler2, M Pfreundschuh8, N Schmitz9. 1. Department of Hematology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg. Electronic address: b.glass@asklepios.com. 2. Institute of Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig. 3. Department of Internal Medicine I, University Hospital Cologne, Cologne. 4. Hospital of Internal Medicine III, Rostock University Hospital, Rostock. 5. Department of Hematology and Oncology, University Hospital Göttingen, Göttingen. 6. Department of Hematology and Oncology, Oldenburg Community Hospital, Oldenburg. 7. Institute of Pathology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck. 8. Saarland University Medical School, Hospital of Medicine I, Homburg, Saar, Germany. 9. Department of Hematology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg.
Abstract
BACKGROUND: We aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: Patients aged 18-60 years and elevated lactate dehydrogenase were treated with four cycles of MegaCHOEP and transplantation of autologous stem cells after cycles 2, 3 and 4. Rituximab (375 mg/m²) was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaCHOEP were compared with 29 patients who had received identical treatment without rituximab. RESULTS: Overall survival (OS) and event-free survival (EFS) after 3 years were significantly improved in patients treated with R-MegaCHOEP (OS: 78.7% versus 55.0%, P = 0.045; EFS: 72.7% versus 47.2%, P = 0.013). In a Cox regression model adjusted for performance status and stage, relative risk of treatment failure was lower (relative risk 0.5, P = 0.041) and OS was better (relative risk 0.4, P = 0.054) for patients given R-MegaCHOEP. Grade 3/4 infections were more frequent in the R-MegaCHOEP group (18.5% versus 6.0%, P = 0.003). CONCLUSIONS: The addition of rituximab to MegaCHOEP significantly improved outcome in young patients with high-risk DLBCL. The higher incidence of grade 3/4 infections needs consideration when rituximab and HDT regimens are combined.
BACKGROUND: We aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: Patients aged 18-60 years and elevated lactate dehydrogenase were treated with four cycles of MegaCHOEP and transplantation of autologous stem cells after cycles 2, 3 and 4. Rituximab (375 mg/m²) was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaCHOEP were compared with 29 patients who had received identical treatment without rituximab. RESULTS: Overall survival (OS) and event-free survival (EFS) after 3 years were significantly improved in patients treated with R-MegaCHOEP (OS: 78.7% versus 55.0%, P = 0.045; EFS: 72.7% versus 47.2%, P = 0.013). In a Cox regression model adjusted for performance status and stage, relative risk of treatment failure was lower (relative risk 0.5, P = 0.041) and OS was better (relative risk 0.4, P = 0.054) for patients given R-MegaCHOEP. Grade 3/4 infections were more frequent in the R-MegaCHOEP group (18.5% versus 6.0%, P = 0.003). CONCLUSIONS: The addition of rituximab to MegaCHOEP significantly improved outcome in young patients with high-risk DLBCL. The higher incidence of grade 3/4 infections needs consideration when rituximab and HDT regimens are combined.
Authors: Jens G Lohr; Petar Stojanov; Michael S Lawrence; Daniel Auclair; Bjoern Chapuy; Carrie Sougnez; Peter Cruz-Gordillo; Birgit Knoechel; Yan W Asmann; Susan L Slager; Anne J Novak; Ahmet Dogan; Stephen M Ansell; Brian K Link; Lihua Zou; Joshua Gould; Gordon Saksena; Nicolas Stransky; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Enrique Hernández-Lemus; Angela Schwarz-Cruz y Celis; Ivan Imaz-Rosshandler; Akinyemi I Ojesina; Joonil Jung; Chandra S Pedamallu; Eric S Lander; Thomas M Habermann; James R Cerhan; Margaret A Shipp; Gad Getz; Todd R Golub Journal: Proc Natl Acad Sci U S A Date: 2012-02-17 Impact factor: 11.205
Authors: Mark Hertzberg; Maher K Gandhi; Judith Trotman; Belinda Butcher; John Taper; Amanda Johnston; Devinder Gill; Shir-Jing Ho; Gavin Cull; Keith Fay; Geoff Chong; Andrew Grigg; Ian D Lewis; Sam Milliken; William Renwick; Uwe Hahn; Robin Filshie; George Kannourakis; Anne-Marie Watson; Pauline Warburton; Andrew Wirth; John F Seymour; Michael S Hofman; Rodney J Hicks Journal: Haematologica Date: 2016-11-10 Impact factor: 9.941
Authors: Patrick J Stiff; Joseph M Unger; James R Cook; Louis S Constine; Stephen Couban; Douglas A Stewart; Thomas C Shea; Pierluigi Porcu; Jane N Winter; Brad S Kahl; Thomas P Miller; Raymond R Tubbs; Deborah Marcellus; Jonathan W Friedberg; Kevin P Barton; Glenn M Mills; Michael LeBlanc; Lisa M Rimsza; Stephen J Forman; Richard I Fisher Journal: N Engl J Med Date: 2013-10-31 Impact factor: 91.245
Authors: K Hohloch; S Zeynalova; G Held; M Ziepert; M Loeffler; G Wulf; N Schmitz; M Pfreundschuh; L Trümper Journal: Leukemia Date: 2014-07-09 Impact factor: 11.528